Immune response to SARS-CoV-2 vaccination in adults from Cali, Colombia: a 2022 experience
Abstract
Introduction: Immunization is a protective measure against SARS-CoV-2. This study assessed IgG anti-S antibodies levels and their association with clinical, demographic and vaccination-related factors in adults from Cali, Colombia (2021-2022).
Objective: To analyze factors associated with binding antibodies levels in adults with a complete SARS-CoV-2 vaccination schedule in a middle-income country city.
Methods: A cross-sectional study was conducted between December 2021 and February 2022 in Cali, Colombia. Eligible adults were identified from a local health database and recruited through random sampling and media outreach. A total of 394 participants were included. Data on demographics, vaccination, and COVID-19 history were collected via interviews and verified with official records. IgG antibodies against the SARS-CoV-2 Spike protein were measured using a standardized ELISA, and results were expressed in BAU/mL following WHO calibration. A cut-off of 1,000 BAU/mL defined high antibody response. Statistical analyses were performed with GraphPad Prism and Stata 14, using logistic regression to explore associations. The study was approved by the Universidad Libre Ethics Committee, and informed consent was obtained from all participants.
Results: Seventy percent of participants showed specific antibodies titers ≥1000 BAU/mL (binding antibodies units). Associations were observed with: a) mRNA vaccines (aOR: 2.40; 95% CI: 0.99–5.84; p = 0.053); b) heterologous vaccination schemes (aOR: 2.39; 95% CI: 1.14–5.02; p < 0.021); and c) ≥21 days since the booster dose (aOR: 2.62; 95% CI: 1.29–5.30; p < 0.007). Women showed a stronger response with heterologous schemes (aOR: 3.27; 95% CI: 0.99–5.84; p = 0.008) and mRNA vaccines (aOR: 3.03; 95% CI: 0.99–5.84; p = 0.048). Among men, antibodies levels were higher when measured ≥21 days after the booster dose (aOR: 2.62; 95% CI: 1.29–5.30; p < 0.007).
Conclusions: mRNA vaccines, heterologous vaccination schedules, and a longer interval since the booster dose were associated with higher anti-S IgG antibodies levels. These findings, relevant to middle-income countries, support the adaptation of vaccination strategies to specific population characteristics.
Downloads
Disciplines:
Epidemiology, ´COVID-19, Immunology, VaccinesReferences
World Health Organization. Strategy to Achieve Global Covid-19 Vaccination by mid-2022. WHO. https://www.who.int/publications/m/item/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022
Szczepanek J, Skorupa M, Goroncy A, Jarkiewicz-tretyn J, Wypych A, et al. Anti-SARS-CoV-2 IgG against the S Protein : A Comparison of vaccines. Vaccines. 2022;10(99):1–26. https://doi.org/10.3390/vaccines10010099
Nikolova M, Todorova Y, Emilova R, Trifonova I, Gladnishka T, Petrova N, et al. Induction of humoral and cellular immune responses to COVID ‐ 19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workers. J Med Virol. 2022;94(5):2008–18. https://doi.org/10.1002/jmv.27572
Ministerio de Salud y de la Protección Social Colombia. Plan Nacional de Vacunación contra COVID-19. MINSALUD. 2021. Available at: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/pnv-contra-covid-19.pdf
Tafur Betancourt LA, Rosero Cundar AS, Remolina Granados SA, Millán M del M, Arévalo M, Lema Flórez E, et al. Características y desenlaces clínicos de pacientes con COVID-19 en la primera ola en Cali, Colombia. Acta Colomb Cuid Intensivo. 2022;22:S36–45. https://doi.org/10.1016/j.acci.2021.12.002
Ministerio de salud y Protección Social Colombia. Vacunación contra COVID-19.MINSALUD. 2021 https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/Vacunacion-covid-19.aspx
Arregocés-castillo L, Fernández-niño J, Rojas-botero M, Palacios-clavijo A, Galvis-pedraza M. Articles Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort. Lancet Healthy Longev. 2022;3(4):e242–52. http://dx.doi.org/10.1016/S2666-7568(22)00035-6
Dulovic A, Kessel B, Harries M, Becker M, Ortmann J, Griesbaum J, et al. Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany. Front Immunol. 2022;13:1–16. http://dx.doi.org/10.3389/fimmu.2022.828053
Chivu‐Economescu M, Bleotu C, Grancea C, Chiriac D, Botezatu A, Iancu IV, et al. Kinetics and persistence of cellular and humoral immune responses to SARS‐CoV‐2 vaccine in healthcare workers with or without prior COVID‐19. J Cellular Molecular Medi 2022;26(4):1293–305. http://dx.doi.org/10.1111/jcmm.17186
Departamento Administrativo Nacional de Estadística. Cali en cifras:Demografía, economia y mercado laboral. DANE. 2002. https://www.dane.gov.co/files/investigaciones/planes-departamentos-ciudades/220322-Foro-Cali-en-cifras.pdf
Ministerio de Salud y de la Protección Social Colombia. SisMuestras. MINSALUD. 2020. https://appmisionales.ins.gov.co/SisMuestras
Instituto Nacional de Salud Colombia. Sivigila INS. 2010. https://www.ins.gov.co/Direcciones/Vigilancia/Paginas/SIVIGILA.aspx
Ministerio de Salud y de la Protección Social Colombia. segCOVID19 Adres. MINSALUD. 2015. https://www.adres.gov.co/
Ministerio de Salud y de la Protección Social Colombia. PAIweb. MINSALUD. 2002. https://paiweb2.paiweb.gov.co/login
Ministerio de Salud y de la Protección Social Colombia. Sispro PISIS .MINSALUD. 2021. https://www.sispro.gov.co/pisis/Pages/pisis-plataforma-de-integración-de-SISPRO.aspx
Open Sourse Epidemiological Statistics for Public Health, Openepi equation. https://www.openepi.com/SampleSize/SSPropor.htm
Bentley EM, Atkinson E, Rigsby P, Elsley W, Bernasconi V, Kristiansen P, et al. Establishment of the 2 nd WHO International Standard for anti-SARS-CoV-2 immunoglobulin and Reference Panel for antibodies to SARS-CoV-2 variants of concern. 2022.
Oliveira-Silva J, Reis T, Lopes R, Batista-Silva R, Marques G. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers. Vaccine. 2022;40(4):650-655. http://dx.doi.org/10.1016/j.vaccine.2021.12.014
Laing ED, Weiss CD, Samuels EC, Coggins SA, Wang W, Wang R, et al. Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers. Emerg Infect Dis. 2022;28(4):828–32. http://dx.doi.org/10.3201/eid2804.212037
Asamoah-Boaheng M, Grunau B, Karim ME, Jassem AN, Bolster J, Marquez AC, et al. Are higher antibody levels against seasonal human coronaviruses associated with a more robust humoral immune response after SARS-CoV-2 vaccination? Front Immunol. 2022;13:954093. http://dx.doi.org/10.3389/fimmu.2022.954093
Bongiovanni M, Liuzzi G, Schiavon L, Gianturco L, Giuliani G. Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection. Journal of Clinical Virology. 2021;143:104962. http://dx.doi.org/10.1016/j.jcv.2021.104962
Bichara CDA, Queiroz MAF, da Silva Graça Amoras E, Vaz GL, Vallinoto IMVC, Bichara CNC, et al. Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil. Vaccines. 2021;9(10):1169. http://dx.doi.org/10.3390/vaccines9101169
Movsisyan M, Harutyunyan H, Movsisyan K, Kasparova I, Hakobyan A, Yenkoyan K. Age-related peculiarities of antibody-mediated humoral immune response following SARS-CoV-2 infection. Exp Gerontol. 2025;203:112735. http://dx.doi.org/10.1016/j.exger.2025.112735
Firinu D, Perra A, Campagna M, Littera R, Meloni F ,et al. Evaluation of Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2:An Observational Study. Vaccines. 2021; 9(12):1478. http://dx.doi.org/10.3390/vaccines9121478
Appelman B, van der Straten K, Lavell AHA, Schinkel M, Slim MA, Poniman M, et al. Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination. eBioMedicine. 2021;72:103589. http://dx.doi.org/10.1016/j.ebiom.2021.103589
Fernández-Ciriza L, González Á, Del Pozo JL, Fernández-Montero A, Carmona-Torre F, Carlos S, et al. Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain. Sci Rep. 2022;12(1):15606. http://dx.doi.org/10.1038/s41598-022-19537-2
Granwehr BP. BioNTech/Pfizer vaccine after Oxford/AZ vaccine increased immune response vs. no second vaccine. Ann Intern Med. 2021;174(11):JC123. http://dx.doi.org/10.7326/ACPJ202111160-123
Herzberg J, Fischer B, Becher H, Becker A-K, Honarpisheh H, Guraya SY, et al. Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study. Front Immunol. 2022;13:896151. http://dx.doi.org/10.3389/fimmu.2022.896151
García-Cruces-Méndez JF, Corral-Gudino L, Del-Amo-Merino MP, Eiros-Bouza JM, Domínguez-Gil González M. SARS-CoV-2 antibody response eight months after vaccination with mRNA vaccines. Influence of prior SARS-CoV-2 exposure. Eur J Intern Med. 2022;97:113-115. http://dx.doi.org/10.1016/j.ejim.2022.01.011
Whitaker HJ, Tsang RSM, Byford R, Andrews NJ, Sherlock J, Sebastian Pillai P, et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. J Infect. 2022;84(5):675–83. http://dx.doi.org/10.1016/j.jinf.2021.12.044
Hibino M, Shigehiro W, Riko K, Shunichi T, et al. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan:A Comparison of Two Assays for Anti-spike Protein mmunoglobulin G. Intern Med. 2022;61(6):811-819.doi:10.21169/internalmedicine.8704-21 http://dx.doi.org/10.2169/internalmedicine.8704-21
Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L, et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun. 2022;13(1):2670. http://dx.doi.org/10.1038/s41467-022-30340-5
Vogel E, Kocher K, Priller A, Cheng C-C, Steininger P, Liao B-H, et al. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2. eBioMedicine. 2022;85:104294. http://dx.doi.org/10.1016/j.ebiom.2022.104294
Saltoğlu N, Dinç HÖ, Balkan İİ, Can G, Özbey D, Beytur AN, et al. Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs. Diagn Microbiol Infect Dis. 2022;104(2):115758. http://dx.doi.org/10.1016/j.diagmicrobio.2022.115758
Rammauro F, Carrión F, Olivero-Deibe N, Fló M, Ferreira A, Pritsch O, et al. Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2. Vaccine. 2022;40(35):5189–96. http://dx.doi.org/10.1016/j.vaccine.2022.07.023
Carrat F, Villarroel PMS, Lapidus N, Fourié T, Blanché H, Dorival C, et al. Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population. Sci Rep. 2022;12(1):8622. http://dx.doi.org/10.1038/s41598-022-11787-4
Kim JY, Kwon J-S, Cha HH, Lim SY, Bae S, Kim S-H. Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19. Korean J Intern Med. 2022;37(6):1234–40. http://dx.doi.org/10.3904/kjim.2022.173
Krsak M, Harry BL, Palmer BE, Franco-Paredes C. Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2. Viral Immunol. 2021;34(8):504–9. http://dx.doi.org/10.1089/vim.2021.0054
Behrens GMN, Barros-Martins J, Cossmann A, Ramos GM, Stankov M V, Odak I, et al. BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. Nat Commun. 2022;13(1):4872. http://dx.doi.org/10.1038/s41467-022-32527-2
Zhao W, Chen W, Li J, Chen M, Li Q, Lv M, et al. Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19. mBio. 2022;13(3):e0018122. http://dx.doi.org/10.1128/mbio.00181-22
Jalkanen P, Kolehmainen P, Haveri A, Huttunen M, Laine L, Österlund P, et al. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination. Microbiol Spectr. 2022;10(2):e0225221. http://dx.doi.org/10.1128/spectrum.02252-21
Neuman F, Rose R, Lopes R, Römpke J, Grobe O, et al. Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination. Vaccines. 2021;9(7):700. http://dx.doi.org/10.3390/vaccines9070700
Casas R. Inmunidad humoral frente a SARS-CoV-2 en trabajadores de centros sociosanitarios de Castilla y León despues de la vacunación con la vacuna de ARNm BNT162b2 de Pfizer/Biontech:e202110141. Rev Esp Salud Pública. 2021;95:e1-12. Available at: https://ojs.sanidad.gob.es/index.php/resp/article/view/610
Ali H, Alahmad B, Al-Shammari AA, Alterki A, Hammad M, Cherian P, et al. Previous COVID-19 Infection and Antibody Levels After Vaccination. Front Public Health. 2021;9:778243. http://dx.doi.org/10.3389/fpubh.2021.778243
Paternina-Caicedo A, Jit M, Alvis-Guzmán N, Fernández JC, Hernández J, Paz-Wilches JJ, et al. Articles Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study. The Lancet Regional Health – Americas. 2022;12: 100296. http://dx.doi.org/10.1016/j.lana.2022.100296
Copyright (c) 2025 Universidad del Cauca
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
.png)
